00:00 / 00:00
Renal tubular acidosis
Minimal change disease
Focal segmental glomerulosclerosis (NORD)
Rapidly progressive glomerulonephritis
IgA nephropathy (NORD)
Acute tubular necrosis
Renal papillary necrosis
Renal cortical necrosis
Chronic kidney disease
Polycystic kidney disease
Multicystic dysplastic kidney
Medullary cystic kidney disease
Medullary sponge kidney
Renal artery stenosis
Renal cell carcinoma
Nephroblastoma (Wilms tumor)
Posterior urethral valves
Hypospadias and epispadias
Lower urinary tract infection
Transitional cell carcinoma
Non-urothelial bladder cancers
Congenital renal disorders: Pathology review
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Acid-base disturbances: Pathology review
Electrolyte disturbances: Pathology review
Renal failure: Pathology review
Nephrotic syndromes: Pathology review
Nephritic syndromes: Pathology review
Urinary incontinence: Pathology review
Urinary tract infections: Pathology review
Kidney stones: Pathology review
Renal and urinary tract masses: Pathology review
Nephroblastoma (Wilms tumor)
0 / 13 complete
nephroblastoma p. 624
Wilms tumor p. 624
dactinomycin for p. 447
neuroblastomas vs p. 357
tumor suppressor genes and p. 222
Tanner Marshall, MS
Wilms’ tumor, or nephroblastoma, is a type of kidney tumor composed of metanephric blastemal cells, cells involved in kidney development, and is the most common malignant kidney tumor in children; only rarely is it seen in adults.
Wilms’ tumor is thought to be caused by mutations in genes responsible for normal genitourinary development, which includes the kidneys as well as the gonads, typically the genes are located around 11p13—which means chromosome 11, the short arm p, region 1, band 3.
One gene critical for normal kidney and gonad development is WT1 (or Wilms’ Tumor 1), which a tumor suppressor gene.
Mutations that result in a “loss of function” of WT1, like deletions, for example, seem to lead to the development of tumor cells seen with Wilms’ tumor.
Wilms’ tumors as a result of WT1 mutations are sometimes part of a developmental syndrome, meaning other abnormalities are present as well, likely because of deletion or mutation of other genes in addition to WT1.
For example, in WAGR syndrome, a mutation in the 11p13 region causes deletion of both WT1 and the PAX6 genes, among others, which leads to Wilms’ tumor and Genitourinary malformations as a result of WT1 deletion, as well as Aniridia (which is absence of iris) and intellectual disability (which is formerly referred to as mental Retardation), as a result of PAX6 deletion.
Another syndrome associated with WT1 mutations is Denys-Drash syndrome, which is characterized by Wilms tumor, early-onset nephrotic syndrome, and male pseudohermaphroditism.
Another gene, WT2, also located on chromosome 11, seems to also be involved with other Wilms’ tumor-containing syndromes, like Beckwith-Wiedemann syndrome, which includes Wilms’ tumor, macroglossia, organomegaly, and hemihypertrophy.
Wilms tumor, also known as nephroblastoma, is a type of kidney cancer that occurs in children. It is common in children under the age of 5, with the majority of cases occurring in children under the age of 3. Wilms tumors tend to be encapsulated and vascularized, and do not cross the midline of the abdomen.
The common symptom of Wilms' tumor is often a painless abdominal growth. However, it may present with abdominal pain and swelling, hematuria, and can metastasize to other organs such as the lungs, the liver, and bones. Nephroblastoma is usually treated with surgery to remove the tumor and, in some cases, chemotherapy and/or radiation therapy.
Copyright © 2023 Elsevier, except certain content provided by third parties
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.